HCC Flashcards
What was the clinical relevance of the Korean study (Yoon et al. JAMA Onc 2018) analyzing EBRT + TACE for HCC?
This study showed that for HCC with vascular invasion, TACE+RT led to improved RR, TTP, and OS compared to Sorafenib.
What population was included in the Korean study (Yoon et al. JAMA Onc 2018) analyzing EBRT + TACE for HCC?
90 pts with HCC with macroscopic vascular invasion
What regimen was included in the Korean study (Yoon et al. JAMA Onc 2018) analyzing EBRT + TACE for HCC?
“<span>→TACE + RT<span> <br></br>vs. <br></br>→sorafenib<br></br><br></br>TACE done q6 weeks with 45 Gy EBRT 3 weeks after first TACE</span></span>”
What were the results of the Korean study (Yoon et al. JAMA Onc 2018) analyzing EBRT + TACE for HCC?
<div>Improved outcomes with EBRT+TACE over Sorafenib</div>
<div><br></br></div>
24-week response rate 33% vs. 2%<div>Median TTP 31 weeks vs. 12 weeks<br></br>Median OS 55 weeks vs. 43 weeks</div>
What was the clinical relevance of the Chinese study (Sun et al. Radiother Onc 2019) analyzing post-op IMRT for HCC with tumor thrombus?
Showed that post-op IMRT after resection of HCC with thrombus improves OS.
What population was included in the Chinese study (Sun et al. Radiother Onc 2019) analyzing post-op IMRT for HCC with tumor thrombus?
52 pts with resected HCC with tumor vein thrombus
What regimen was included in the Chinese study (Sun et al. Radiother Onc 2019) analyzing post-op IMRT for HCC with tumor thrombus?
“<span>partial hepatectomy ± thrombectomy →<br></br><br></br>→post-op IMRT<br></br>vs. <br></br>→obs</span>”
What were the results of the Chinese study (Sun et al. Radiother Onc 2019) analyzing post-op IMRT for HCC with tumor thrombus?
<div>Improved OS with use of post-op IMRT:</div>
<div><br></br></div>
1, 2, 3-yr OS <br></br>77%/19%/12% vs. 27%/12%/0%<br></br><br></br>Median OS 18.9 vs. 10.8 mos<br></br><br></br>
What was the clinical relevance of the Chinese study (Wei et al. JCO 2019) analyzing pre-op EBRT for HCC with tumor thrombus?
Showed that pre-op RT in HCC with tumor vein thrombosis improved OS and disease control.
What population was included in the Chinese study (Wei et al. JCO 2019) analyzing pre-op EBRT for HCC with tumor thrombus?
164 pts with resectable HCC with tumor vein thrombus
What regimen was included in the Chinese study (Wei et al. JCO 2019) analyzing pre-op EBRT for HCC with tumor thrombus?
“<span>→pre-op RT 18 Gy/6 fx, 3DCRT<span><br></br>vs.<br></br>→no RT<br></br><br></br>surgery 1 month after RT</span></span>”
What were the results of the Chinese study (Wei et al. JCO 2019) analyzing pre-op EBRT for HCC with tumor thrombus?
<div>OS improved with preop EBRT:</div>
<div><br></br></div>
1-yr OS 75% vs. 43%<br></br>2-yr OS 27% vs. 9%<br></br><div>2-yr DFS 13% vs. 3%</div><div><br></br>RT caused grade 3 toxicity in 2 patients that led to inoperability</div>
What was the clinical relevance of the Italian study analyzing SBRT vs TACE for HCC after TACE failure?
Showed that SBRT improved LC compared to TAE/TACE after incomplete response to TACE.
What population was included in the Italian study analyzing SBRT vs TACE for HCC after TACE failure?
40 pts with unresectable HCC s/p TAE/TACE and incomplete response
What regimen was included in the Italian study analyzing SBRT vs TACE for HCC after TACE failure?
“after incomplete response to TAE/TACE:<br></br><br></br><span>SBRT </span>vs. TAE/TACE”